Developer docs
API playgroundTry for free, no card

Search company profiles

Kanaph Therapeutics

Full company profile

uuid0002izj

Namestring
Kanaph Therapeutics
Legal namestring
KANAPH Therapeutics Inc.
Websiteurl
kanaphtx.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Kanaph Therapeutics is a Seoul-based clinical-stage biotech founded in February 2019 by Byoung Chul Lee that develops large- and small-molecule therapeutics for oncology, autoimmune, and ophthalmic diseases using a genome-based drug discovery approach. The company operates four proprietary technology pillars — Human Genome Analysis (GWAS/PheWAS plus ML validation against 23andMe and UK Biobank data), Bispecific Antibody Technology (including the TMEkine antibody-cytokine fusion platform), Small-Molecule Drug Technology, and the SoluFlex LinK ADC platform (co-developed with Lotte Biologics) — feeding a seven-asset pipeline that spans FAP-targeted IL-12 cytokine fusion (KNP-101), C3b/VEGF bispecific Fc-fusion for AMD (KNP-301), EP2/EP4 and SHP2/SOS1 small-molecule oncology candidates (KNP-502/503/504), and a bispecific EGFRxcMET ADC (KNP-701).

The company's revenue model is a relay-style out-licensing approach: preclinical assets are licensed to Korean pharmaceutical partners (Dong-A ST, Oscotec, Yuhan, GC Biopharma, Lotte Biologics) for upfront and milestone payments, after which Kanaph may pursue early clinical development independently or with partners and target secondary global technology transfer. Cumulative upfront payments of approximately KRW 15.9 billion have been collected from five licensing agreements with aggregate deal value exceeding KRW 774.8 billion, and the company raised an additional KRW 40 billion (~$26.7M) via KOSDAQ IPO in March 2026 to fund clinical development and pipeline expansion. Net loss was KRW 28.3 billion in 2024, with management targeting profitability by 2028.

The company serves two customer segments: pharmaceutical partners that license assets for late-stage development and commercialization, and indirectly patients with solid tumors (NSCLC, CRC, pancreatic, head & neck, esophageal, glioblastoma), RAS-mutated cancers, and retinal diseases (wet AMD, geographic atrophy, DME). Operating from a Seoul headquarters plus Gwanggyo and Dongtan R&D centers, the company employs 11–50 staff and has secured KDDF national project funding, FDA IND approval for KNP-502, and strategic equity investments from Lotte Biologics and GC Biopharma alongside its public listing.

Short descriptiontext

Kanaph Therapeutics is a Seoul-based clinical-stage biotech developing genome-discovered bispecific antibodies, small molecules, and ADCs for oncology and ophthalmology, generating revenue through early out-licensing deals with Korean pharmaceutical partners and targeting global technology transfer.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersYongsan, South Korea
HQ citystring
Yongsan
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, antibody drug conjugates, bispecific antibody therapy, drug licensing services, biopharmaceutical research
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing/Out-licensing
TypeLicensing Royalties
Description

The company generates revenue through technology out-licensing deals with pharmaceutical companies, receiving upfront payments, milestone payments tied to development and regulatory achievements, and future royalties from product sales. Deals include transfers to Oscotec (KNP-502), Dong-A ST (KNP-101), Yuhan (KNP-504), and co-development agreements with GC Biopharma and Lotte Biologics.

koreabiomed.com
2IPO Proceeds
TypeOne Time License
Description

Raised KRW 40 billion (US$26.7 million) through Kosdaq IPO in March 2026, with all proceeds directed to fund operations and clinical development programs. The IPO implied a market capitalization of USD 179.45 million.

bioworld.com
3Research Service Fees
TypeProfessional Services
Description

The company conducts joint R&D with pharmaceutical partners and receives funding for research services as part of co-development agreements.

koreabiomed.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kanaph Therapeutics is a genome-based biotech company that discovers and develops multi-modality drug candidates (bispecific antibodies, small molecules, and antibody-drug conjugates) targeting oncology, autoimmune, and ophthalmology indications. The company operates a relay-style business model that transfers drug candidate technology at non-clinical stage to domestic pharmaceutical partners via licensing and co-development agreements, while advancing additional candidates through early clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • KNP-301 demonstrated ~3.5x stronger complement inhibition (IC50) vs Syfovre and ~4.7x vs Izervay in preclinical studies
+1 more record
Product overview1 text field

Kanaph Therapeutics is a genome-based biotech company developing a multi-modality drug portfolio including bispecific antibodies, small-molecule inhibitors, and antibody-drug conjugates (ADCs) for oncology and ophthalmology. The core technology platform combines human genome analysis for target discovery with three therapeutic modalities: the TMEkine™ bispecific antibody-cytokine platform, SoluFlex LinK™ ADC platform (co-developed with Lotte Biologics), and small-molecule drug discovery. The pipeline spans six clinical-stage candidates: KNP-101 (FAP-IL12 bispecific, partnered with Dong-A ST), KNP-301 (C3b-VEGF bispecific for AMD), KNP-502 (EP2/EP4 dual inhibitor, licensed to Oscotec), KNP-503 (SHP2 inhibitor), KNP-504 (SOS1 inhibitor, licensed to Yuhan), and KNP-701 (EGFR×cMET bispecific ADC, partnered with GC Biopharma). The company operates a relay-type business model with early-stage technology out-licensing followed by clinical development and global technology transfer.

Product and service10 records
1TMEkine™ Platform
CategoryTechnology Platform
Description

Antibody-cytokine fusion protein platform for developing immunotherapies that overcome immunosuppressive tumor microenvironment. Used for bispecific antibody candidates targeting cold tumors; out-licensed to partners including Dong-A ST.

2SoluFlex LinK™ ADC Platform
CategoryADC Platform
Description

Hydrophilic linker and novel payload ADC platform co-developed with Lotte Biologics to overcome limitations of current ADC therapies, improving solubility, PK, stability, and productivity. Offered to external ADC developers as a toolbox.

3Human Genome Analysis Platform
CategoryCore Technology Platform
Description

Disease signature discovery platform leveraging human genomic databases and bioinformatics to identify drug targets with high likelihood of clinical success.

4Small-Molecule Drug Technology
CategoryTechnology Platform
Description

Efficient compound screening platform integrating design, synthesis, evaluation, analysis, feedback, and library/database development for small-molecule drug discovery.

5KNP-101
CategoryPipeline Candidate (Immuno-Oncology)
Description

First-in-class FAP-targeted IL-12 cytokine therapy for solid tumors with immunosuppressive tumor microenvironment, designed to minimize systemic toxicity. Licensed to Dong-A ST.

6KNP-301
CategoryPipeline Candidate (Ophthalmology)
Description

Bispecific Fc-fusion protein combining C3b blocker and VEGF blocker for wet AMD, geographic atrophy (GA), and diabetic macular edema (DME).

7KNP-502
CategoryPipeline Candidate (Small Molecule)
Description

Best-in-class dual EP2 and EP4 prostaglandin receptor antagonist designed to overcome PGE2-mediated immunosuppression in the tumor microenvironment. Licensed to Oscotec Inc.

8KNP-503
CategoryPipeline Candidate (Small Molecule)
Description

Best-in-class SHP2 allosteric inhibitor for KRAS-mutated cancers including NSCLC, CRC, and glioblastoma, available in brain-penetrant and non-brain-penetrant versions.

9KNP-504
CategoryPipeline Candidate (Small Molecule)
Description

Best-in-class SOS1 inhibitor for RAS-mutated cancers including NSCLC, CRC, PDAC, and NF1-mutant solid tumors. Licensed to Yuhan Corporation.

10KNP-701
CategoryPipeline Candidate (ADC)
Description

Anti-cMET and anti-EGFR bispecific ADC for NSCLC targeting drug-resistant EGFR-mutant and cMET-overexpressing cancers with optimized hydrophilic linkers and DAR6 payload. Co-developed with GC Biopharma.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-04-21
Description

Data provision agreement for human genomic data analysis. 23andMe provides non-identified genomic data from 11 million+ individuals to support Kanaph's disease signature discovery system for next-generation ADC and immuno-oncology target identification.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-06-16
Description

Three-party MOU with Lotte Biologics and Axcelead (CRO spun off from Takeda) to build ADC toolbox. Axcelead contributes Takeda's legacy library of 1.2M+ compounds for novel payload discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-17
Description

Joint development agreement with option rights for EGFRxcMET bispecific ADC (KNP-701) targeting NSCLC. GC Biopharma exercised its option in December 2025 to advance the preclinical pipeline into development stage. CMC development led by Kanaph; clinical development by GC Biopharma.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-03-07
Description

Licensed SOS1 inhibitor KNP-504 to Yuhan Corporation for RAS-mutated cancers. Total contract value KRW 2,080 billion including KRW 60 billion upfront plus milestones. Jointly developed with Cyrus Therapeutics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-27
Description

Lotte Biologics participated as a new strategic investor in Kanaph's Series C funding (KRW 23 billion). The companies co-developed the SoluFlex LinK ADC platform with hydrophilic linkers and novel payloads to overcome limitations of current ADCs. Expanded to second joint R&D agreement in 2025, with plans to provide ADC toolbox services to external developers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Jointly developed SOS1 inhibitor KNP-504 with Cyrus Therapeutics. Both companies contributed preclinical candidates; jointly presented data at AACR showing superior efficacy vs competitors.

7Dong-A ST
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-12-21
Description

Licensed FAP-IL12mut KNP-101 (DA-3101) to Dong-A ST for solid tumor development. Deal includes joint research and licensing components. KNP-101 demonstrated favorable safety profile with reduced systemic toxicity in preclinical studies.

koreabiomed.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-03-31
Description

Licensed EP2/4 dual inhibitor KNP-502 (OCT-598) to Oscotec for global development. Received KRW 2 billion upfront payment with additional milestones and royalties. KNP-502 received FDA IND approval for solid tumors in May 2025; first patient dosing planned for Q4 2025.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-09-15
Description

CDO (Contract Development Organization) agreement for KNP-301 retinal disease drug development, covering entire process from cell line development to clinical material manufacturing. First drug substance project for a biotech venture.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2019-10-23
Description

Technology transfer agreement for next-generation anticancer drug candidate technology from Prof. Kyoung-Hoon Min's research team. Provides access to academic research capabilities.

Strategic tierSupportingTypeOthers
Description

Selected for multiple KDDF national projects including: SHP2 allosteric inhibitor development (2022), FAP-IL12 variant fusion protein development (2022), and SOS1 inhibitor development (2023). Receives government R&D funding support.

12Yungjin Pharm (영진약품)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Two-year joint research collaboration on SHP2 allosteric inhibitor development, contributing synthetic chemistry expertise. Selected for KDDF national project support.

kanaphtx.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

South Korean clinical-stage biotech focused on bispecific antibodies for oncology and neuro-degeneration. Directly comparable to Kanaph's bispecific antibody platform (TMEkine, KNP-301, KNP-701), similar size, stage, and Korean biotech ecosystem with overlapping investor base.

TypeDirect peer
Description

Clinical-stage US biotech developing RAS(ON) inhibitors including SOS1-targeted candidates (RMC-6291, RMC-6236). Direct mechanistic competitor for KNP-504 and adjacent to KNP-503 SHP2 program; validates commercial interest in RAS pathway inhibition.

TypeDirect peer
Description

Clinical-stage oncology biotech focused on the RAS/MAPK pathway including SHP2 inhibitors (ERAS-601) and downstream targets. Directly comparable to Kanaph's KNP-503 SHP2 program and overall KRAS-mutated solid tumor strategy.

TypeDirect peer
Description

US biotech with FDA-approved complement C3 inhibitor Syfovre for geographic atrophy and Empaveli for PNH. Direct comparator for Kanaph's KNP-301 C3b/VEGF bispecific for AMD, with benchmark preclinical IC50 data (Syfovre) cited in Kanaph's value proposition.

TypeDirect peer
Description

Developed Izervay (avacincaptad pegol), a C5 complement inhibitor approved for geographic atrophy, now part of Astellas. Direct clinical-stage competitor to KNP-301 in AMD/GA with benchmark IC50 data cited in Kanaph's value proposition.

TypeDirect peer
Description

Clinical-stage US ADC biotech developing novel linker-payload platforms (Dolasynthen, Immunosynthen). Directly comparable to Kanaph's SoluFlex LinK ADC platform strategy of differentiating through proprietary linker chemistry.

TypeDirect peer
Description

Clinical-stage US biotech developing ADC therapeutics including EGFR×cMET bispecific ADC programs. Direct competitor to Kanaph's KNP-701 EGFR×cMET bispecific ADC partnered with GC Biopharma.

TypeBroad incumbent
Description

Acquired by BMS for $4.8B in 2024, develops KRAZATI (adagrasib) and earlier-stage SOS1 inhibitors. Large incumbent in the same RAS-mutated cancer space where Kanaph's KNP-504 competes; validates the market but raises the competitive bar.

TypeBroad incumbent
Description

Global leader in bispecific antibodies with approved assets (Vabysmo for AMD, Linvoseltamab). Sets clinical and commercial benchmark for both KNP-301 (AMD) and Kanaph's broader bispecific antibody pipeline strategy.

TypeEmerging player
Description

Commercial-stage US biotech pursuing genetically targeted oncology therapies with multiple programs in RAS-mutated cancers and rare diseases. Comparable business model of targeting genetically defined patient populations with partnered/out-licensed programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kanaph Therapeutics

Biopharmaceuticalskanaphtx.com

Kanaph Therapeutics is a Seoul-based clinical-stage biotech developing genome-discovered bispecific antibodies, small molecules, and ADCs for oncology and ophthalmology, generating revenue through early out-licensing deals with Korean pharmaceutical partners and targeting global technology transfer.

What Kanaph Therapeutics does

Kanaph Therapeutics is a Seoul-based clinical-stage biotech founded in February 2019 by Byoung Chul Lee that develops large- and small-molecule therapeutics for oncology, autoimmune, and ophthalmic diseases using a genome-based drug discovery approach. The company operates four proprietary technology pillars — Human Genome Analysis (GWAS/PheWAS plus ML validation against 23andMe and UK Biobank data), Bispecific Antibody Technology (including the TMEkine antibody-cytokine fusion platform), Small-Molecule Drug Technology, and the SoluFlex LinK ADC platform (co-developed with Lotte Biologics) — feeding a seven-asset pipeline that spans FAP-targeted IL-12 cytokine fusion (KNP-101), C3b/VEGF bispecific Fc-fusion for AMD (KNP-301), EP2/EP4 and SHP2/SOS1 small-molecule oncology candidates (KNP-502/503/504), and a bispecific EGFRxcMET ADC (KNP-701).

The company's revenue model is a relay-style out-licensing approach: preclinical assets are licensed to Korean pharmaceutical partners (Dong-A ST, Oscotec, Yuhan, GC Biopharma, Lotte Biologics) for upfront and milestone payments, after which Kanaph may pursue early clinical development independently or with partners and target secondary global technology transfer. Cumulative upfront payments of approximately KRW 15.9 billion have been collected from five licensing agreements with aggregate deal value exceeding KRW 774.8 billion, and the company raised an additional KRW 40 billion (~$26.7M) via KOSDAQ IPO in March 2026 to fund clinical development and pipeline expansion. Net loss was KRW 28.3 billion in 2024, with management targeting profitability by 2028.

The company serves two customer segments: pharmaceutical partners that license assets for late-stage development and commercialization, and indirectly patients with solid tumors (NSCLC, CRC, pancreatic, head & neck, esophageal, glioblastoma), RAS-mutated cancers, and retinal diseases (wet AMD, geographic atrophy, DME). Operating from a Seoul headquarters plus Gwanggyo and Dongtan R&D centers, the company employs 11–50 staff and has secured KDDF national project funding, FDA IND approval for KNP-502, and strategic equity investments from Lotte Biologics and GC Biopharma alongside its public listing.

Kanaph Therapeutics firmographics

Firmographics
Name
Kanaph Therapeutics
Legal name
KANAPH Therapeutics Inc.
Website
https://kanaphtx.com
Company type
Public
Founded year
2019
Operating status
Ipo
Headcount range
11–50 employees
Short description
Kanaph Therapeutics is a Seoul-based clinical-stage biotech developing genome-discovered bispecific antibodies, small molecules, and ADCs for oncology and ophthalmology, generating revenue through early out-licensing deals with Korean pharmaceutical partners and targeting global technology transfer.
Ownership category
akta.pro rank

Kanaph Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncology drug development
  • Antibody drug conjugates
  • Bispecific antibody therapy
  • Drug licensing services
  • Biopharmaceutical research

Where Kanaph Therapeutics is headquartered

Location

Headquarters

HQ city
Yongsan
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Kanaph Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Technology Licensing/Out-licensing: The company generates revenue through technology out-licensing deals with pharmaceutical companies, receiving upfront payments, milestone payments tied to development and regulatory achievements, and future royalties from product sales. Deals include transfers to Oscotec (KNP-502), Dong-A ST (KNP-101), Yuhan (KNP-504), and co-development agreements with GC Biopharma and Lotte Biologics.
  2. IPO Proceeds: Raised KRW 40 billion (US$26.7 million) through Kosdaq IPO in March 2026, with all proceeds directed to fund operations and clinical development programs. The IPO implied a market capitalization of USD 179.45 million.
  3. Research Service Fees: The company conducts joint R&D with pharmaceutical partners and receives funding for research services as part of co-development agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Kanaph Therapeutics product offering

Product offering

Core offering

Kanaph Therapeutics is a genome-based biotech company that discovers and develops multi-modality drug candidates (bispecific antibodies, small molecules, and antibody-drug conjugates) targeting oncology, autoimmune, and ophthalmology indications. The company operates a relay-style business model that transfers drug candidate technology at non-clinical stage to domestic pharmaceutical partners via licensing and co-development agreements, while advancing additional candidates through early clinical trials.

Product overview

Kanaph Therapeutics is a genome-based biotech company developing a multi-modality drug portfolio including bispecific antibodies, small-molecule inhibitors, and antibody-drug conjugates (ADCs) for oncology and ophthalmology. The core technology platform combines human genome analysis for target discovery with three therapeutic modalities: the TMEkine™ bispecific antibody-cytokine platform, SoluFlex LinK™ ADC platform (co-developed with Lotte Biologics), and small-molecule drug discovery. The pipeline spans six clinical-stage candidates: KNP-101 (FAP-IL12 bispecific, partnered with Dong-A ST), KNP-301 (C3b-VEGF bispecific for AMD), KNP-502 (EP2/EP4 dual inhibitor, licensed to Oscotec), KNP-503 (SHP2 inhibitor), KNP-504 (SOS1 inhibitor, licensed to Yuhan), and KNP-701 (EGFR×cMET bispecific ADC, partnered with GC Biopharma). The company operates a relay-type business model with early-stage technology out-licensing followed by clinical development and global technology transfer.

Differentiator

Problem solved

Functional benefit

Products and services

  • TMEkine™ Platform Antibody-cytokine fusion protein platform for developing immunotherapies that overcome immunosuppressive tumor microenvironment. Used for bispecific antibody candidates targeting cold tumors; out-licensed to partners including Dong-A ST.
  • SoluFlex LinK™ ADC Platform Hydrophilic linker and novel payload ADC platform co-developed with Lotte Biologics to overcome limitations of current ADC therapies, improving solubility, PK, stability, and productivity. Offered to external ADC developers as a toolbox.
  • Human Genome Analysis Platform Disease signature discovery platform leveraging human genomic databases and bioinformatics to identify drug targets with high likelihood of clinical success.
  • Small-Molecule Drug Technology Efficient compound screening platform integrating design, synthesis, evaluation, analysis, feedback, and library/database development for small-molecule drug discovery.
  • KNP-101 First-in-class FAP-targeted IL-12 cytokine therapy for solid tumors with immunosuppressive tumor microenvironment, designed to minimize systemic toxicity. Licensed to Dong-A ST.
  • KNP-301 Bispecific Fc-fusion protein combining C3b blocker and VEGF blocker for wet AMD, geographic atrophy (GA), and diabetic macular edema (DME).
  • KNP-502 Best-in-class dual EP2 and EP4 prostaglandin receptor antagonist designed to overcome PGE2-mediated immunosuppression in the tumor microenvironment. Licensed to Oscotec Inc.
  • KNP-503 Best-in-class SHP2 allosteric inhibitor for KRAS-mutated cancers including NSCLC, CRC, and glioblastoma, available in brain-penetrant and non-brain-penetrant versions.
  • KNP-504 Best-in-class SOS1 inhibitor for RAS-mutated cancers including NSCLC, CRC, PDAC, and NF1-mutant solid tumors. Licensed to Yuhan Corporation.
  • KNP-701 Anti-cMET and anti-EGFR bispecific ADC for NSCLC targeting drug-resistant EGFR-mutant and cMET-overexpressing cancers with optimized hydrophilic linkers and DAR6 payload. Co-developed with GC Biopharma.

Quantifiable outcome

  • KNP-301 demonstrated ~3.5x stronger complement inhibition (IC50) vs Syfovre and ~4.7x vs Izervay in preclinical studies
  • +1 more outcomes

Companies that use Kanaph Therapeutics

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Kanaph Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Kanaph Therapeutics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered major, supporting and core.

  • 23andMemajorTechnology or Integration · 21 April 2026Data provision agreement for human genomic data analysis. 23andMe provides non-identified genomic data from 11 million+ individuals to support Kanaph's disease signature discovery system for next-generation ADC and immuno-oncology target identification.
  • AxceleadsupportingStrategic or Co-development Partner · 16 June 2025Three-party MOU with Lotte Biologics and Axcelead (CRO spun off from Takeda) to build ADC toolbox. Axcelead contributes Takeda's legacy library of 1.2M+ compounds for novel payload discovery.
  • GC Biopharma (녹십자)coreStrategic or Co-development Partner · 17 December 2024Joint development agreement with option rights for EGFRxcMET bispecific ADC (KNP-701) targeting NSCLC. GC Biopharma exercised its option in December 2025 to advance the preclinical pipeline into development stage. CMC development led by Kanaph; clinical development by GC Biopharma.
  • Yuhan CorporationcoreOEM/ Whitelabel/ Licensing Partner · 7 March 2024Licensed SOS1 inhibitor KNP-504 to Yuhan Corporation for RAS-mutated cancers. Total contract value KRW 2,080 billion including KRW 60 billion upfront plus milestones. Jointly developed with Cyrus Therapeutics.
  • Lotte BiologicscoreStrategic or Co-development Partner · 27 December 2023Lotte Biologics participated as a new strategic investor in Kanaph's Series C funding (KRW 23 billion). The companies co-developed the SoluFlex LinK ADC platform with hydrophilic linkers and novel payloads to overcome limitations of current ADCs. Expanded to second joint R&D agreement in 2025, with plans to provide ADC toolbox services to external developers.
  • Cyrus Therapeutics (사이러스테라퓨틱스)coreStrategic or Co-development Partner · 1 January 2023Jointly developed SOS1 inhibitor KNP-504 with Cyrus Therapeutics. Both companies contributed preclinical candidates; jointly presented data at AACR showing superior efficacy vs competitors.
  • Dong-A STcoreOEM/ Whitelabel/ Licensing Partner · 21 December 2022Licensed FAP-IL12mut KNP-101 (DA-3101) to Dong-A ST for solid tumor development. Deal includes joint research and licensing components. KNP-101 demonstrated favorable safety profile with reduced systemic toxicity in preclinical studies.
  • OscoteccoreOEM/ Whitelabel/ Licensing Partner · 31 March 2022Licensed EP2/4 dual inhibitor KNP-502 (OCT-598) to Oscotec for global development. Received KRW 2 billion upfront payment with additional milestones and royalties. KNP-502 received FDA IND approval for solid tumors in May 2025; first patient dosing planned for Q4 2025.
  • Samsung BiologicsmajorStrategic or Co-development Partner · 15 September 2020CDO (Contract Development Organization) agreement for KNP-301 retinal disease drug development, covering entire process from cell line development to clinical material manufacturing. First drug substance project for a biotech venture.
  • Chung-Ang UniversitysupportingStrategic or Co-development Partner · 23 October 2019Technology transfer agreement for next-generation anticancer drug candidate technology from Prof. Kyoung-Hoon Min's research team. Provides access to academic research capabilities.
  • KDDF (Korea Drug Development Fund)supportingOthersSelected for multiple KDDF national projects including: SHP2 allosteric inhibitor development (2022), FAP-IL12 variant fusion protein development (2022), and SOS1 inhibitor development (2023). Receives government R&D funding support.
  • Yungjin Pharm (영진약품)supportingStrategic or Co-development PartnerTwo-year joint research collaboration on SHP2 allosteric inhibitor development, contributing synthetic chemistry expertise. Selected for KDDF national project support.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Kanaph Therapeutics competitors and assessment

Company assessment

Direct peers

  • ABL Bio: South Korean clinical-stage biotech focused on bispecific antibodies for oncology and neuro-degeneration. Directly comparable to Kanaph's bispecific antibody platform (TMEkine, KNP-301, KNP-701), similar size, stage, and Korean biotech ecosystem with overlapping investor base.
  • Revolution Medicines: Clinical-stage US biotech developing RAS(ON) inhibitors including SOS1-targeted candidates (RMC-6291, RMC-6236). Direct mechanistic competitor for KNP-504 and adjacent to KNP-503 SHP2 program; validates commercial interest in RAS pathway inhibition.
  • Erasca: Clinical-stage oncology biotech focused on the RAS/MAPK pathway including SHP2 inhibitors (ERAS-601) and downstream targets. Directly comparable to Kanaph's KNP-503 SHP2 program and overall KRAS-mutated solid tumor strategy.
  • Apellis Pharmaceuticals: US biotech with FDA-approved complement C3 inhibitor Syfovre for geographic atrophy and Empaveli for PNH. Direct comparator for Kanaph's KNP-301 C3b/VEGF bispecific for AMD, with benchmark preclinical IC50 data (Syfovre) cited in Kanaph's value proposition.
  • Iveric Bio (Astellas): Developed Izervay (avacincaptad pegol), a C5 complement inhibitor approved for geographic atrophy, now part of Astellas. Direct clinical-stage competitor to KNP-301 in AMD/GA with benchmark IC50 data cited in Kanaph's value proposition.
  • Mersana Therapeutics: Clinical-stage US ADC biotech developing novel linker-payload platforms (Dolasynthen, Immunosynthen). Directly comparable to Kanaph's SoluFlex LinK ADC platform strategy of differentiating through proprietary linker chemistry.
  • Pyxis Oncology: Clinical-stage US biotech developing ADC therapeutics including EGFR×cMET bispecific ADC programs. Direct competitor to Kanaph's KNP-701 EGFR×cMET bispecific ADC partnered with GC Biopharma.

Broad incumbents

  • Mirati Therapeutics (Bristol-Myers Squibb): Acquired by BMS for $4.8B in 2024, develops KRAZATI (adagrasib) and earlier-stage SOS1 inhibitors. Large incumbent in the same RAS-mutated cancer space where Kanaph's KNP-504 competes; validates the market but raises the competitive bar.
  • Regeneron Pharmaceuticals: Global leader in bispecific antibodies with approved assets (Vabysmo for AMD, Linvoseltamab). Sets clinical and commercial benchmark for both KNP-301 (AMD) and Kanaph's broader bispecific antibody pipeline strategy.

Emerging players

  • BridgeBio Pharma: Commercial-stage US biotech pursuing genetically targeted oncology therapies with multiple programs in RAS-mutated cancers and rare diseases. Comparable business model of targeting genetically defined patient populations with partnered/out-licensed programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Kanaph Therapeutics social profiles

Digital presence

Kanaph Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kanaph Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Kanaph Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kanaph Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kanaph Therapeutics

What does Kanaph Therapeutics do?

Kanaph Therapeutics is a genome-based biotech company that discovers and develops multi-modality drug candidates (bispecific antibodies, small molecules, and antibody-drug conjugates) targeting oncology, autoimmune, and ophthalmology indications. The company operates a relay-style business model that transfers drug candidate technology at non-clinical stage to domestic pharmaceutical partners via licensing and co-development agreements, while advancing additional candidates through early clinical trials.

Is Kanaph Therapeutics a public or private company?

Kanaph Therapeutics is a public company. It is classified as public and is currently ipo.

When was Kanaph Therapeutics founded?

Kanaph Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Kanaph Therapeutics based?

Kanaph Therapeutics is headquartered in Yongsan, South Korea, in the Asia region.

How does Kanaph Therapeutics make money?

Three revenue lines are on record. Technology Licensing/Out-licensing is the primary driver. The others are IPO Proceeds and research Service Fees.

Who are Kanaph Therapeutics's main competitors?

Direct peers on record are ABL Bio, Revolution Medicines, Erasca, Apellis Pharmaceuticals, Iveric Bio (Astellas), Mersana Therapeutics and Pyxis Oncology. Broad incumbents are Mirati Therapeutics (Bristol-Myers Squibb) and Regeneron Pharmaceuticals. BridgeBio Pharma is listed as an emerging player.

Does Kanaph Therapeutics have an API?

No public API is recorded for Kanaph Therapeutics.

What industry is Kanaph Therapeutics in?

Kanaph Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingKanaph Therapeutics Vice President Changwon Park Raises Stake to 0.47% From 0.46%Kanaph Therapeutics Vice President Changwon Park increased his stake to 0.47% from 0.46% by buying 3,000 common shares on October 30, 2026, at KRW 8,900 per share. His holdings totaled 63,000 shares as of November 2, 2026.BioWorldKanaph’s $27M IPO to aid multi-modality cancer, immune portfolioKanaph Therapeutics Inc. raised ₩40 billion (US$26.7 million) through its Kosdaq stock sale on March 16, becoming the first Korean biotech to go public this year. The Seoul-based multi-modality platform company's shares climbed to ₩70,000 in intraday trading before closing at ₩50,600, representing a 153% gain over the offering price. The IPO proceeds will support the development of Kanaph's cancer and immune therapy portfolio.IpoxKanaph Therapeutics — IPOXKANAPH Therapeutics Inc, a South Korean biotechnology company specializing in targeted cancer therapies, plans to list on the KOSDAQ exchange on March 16, 2026, offering 2 million shares at KRW 20,000 per share to raise approximately KRW 40 billion (USD 27.68 million). The IPO implies a market capitalization of USD 179.45 million, with all offering proceeds directed to the company to fund its operations and clinical development programs. The company's lead candidate KNP-101 is a first-in-class FAP-targeted IL-12 therapy in development for solid tumors including non-small cell lung cancer and colorectal cancer.뉴스톱Canaptera, public offering price confirmed at the upper limit... Will the bio venture wind continue - News TopKanaph Therapeutics, a Korean human genome-based innovative drug development company established in 2019, has confirmed its public offering price at 20,000 won (the upper end of its 16,000–20,000 won band) and is set to list on the KOSDAQ market on the 16th. The company has raised cumulative investment of approximately 61.6 billion won from major strategic investors including Green Cross (13%), Dong-A ST, and Lotte Biologics, as well as financial investors such as Premier Partners (8.2%), Kolon Investment (7%), and Intervest (5%). The listing is being closely watched as the first bio IPO of the year and a test bed for gauging market investment sentiment in the bio sector following successful offerings in the second half of last year.KBRGenome-driven biotech Kanaph maps Kosdaq debut, targets global out-licensing after domestic clinical runsKanaph Therapeutics, a South Korean genome-driven biotech company, announced plans for a Kosdaq IPO offering 2 million shares at 16,000-20,000 won each to raise up to 40 billion won, with listing expected on March 16. The company has established five licensing agreements with Korean pharmaceutical companies worth approximately 774.8 billion won in cumulative deal value, and operates a relay-style model of preclinical out-licensing followed by clinical development and secondary global out-licensing. Despite reporting a net loss of 28.3 billion won in 2024, the company targets profitability by 2028 with seven pipelines including bispecific antibodies and ADCs targeting clinical entry in 2027.AsiaeKanaph Bets on Genome-Based Drug Development... Aims for Profitability by 2028Kanaph Therapeutics, a South Korean biotech company specializing in genome-based drug development, is listing on KOSDAQ next month with a target offering price of 16,000–20,000 won per share, seeking to raise between 32 billion and 40 billion won. The company operates a relay-type business model that transfers technology to domestic pharmaceutical firms at the non-clinical stage, then pursues early clinical trials independently or in partnership before seeking global technology transfer, reducing development risks and increasing capital efficiency. Kanaph projects profitability by 2028 and currently operates seven pipelines including bispecific antibodies, small molecules, and antibody-drug conjugates, with existing partnerships with Lotte Biologics, Oscotec, Dong-A ST, and Yuhan Corporation.HitnewsKanaph Therapeutics secures 23 billion won in Series C funding... Lotte Bio, new SIKanaph Therapeutics secured 23 billion won in Series C funding while advancing its drug development pipeline. The company is jointly developing next-generation immune anticancer drugs with Lotte Biologics and previously transferred assets to Dong-A ST and Oscotec.EconomistKanaph Therapeutics secures 23 billion won in Series C funding... Lotte Bio participates as a new strategic investor.Kanaph Therapeutics secured 23 billion won in a Series C funding round, with participation from existing strategic investor GC Green Cross and new strategic investor Lotte Biologics. The capital will be used to advance the company's drug pipeline into clinical stages and support research for future technology transfers.PR NewswireImmunocytokines Markets, 2030Research and Markets has published a market research report analyzing the global immunocytokines market from 2020 to 2030, covering therapeutic candidates being developed for rheumatoid arthritis and various cancer types. The report examines the current development pipeline, profiles key players including Genopharm, ImmunGene, Kanaph Therapeutics, Merck KGaA, and Philogen, and provides market forecasts across conservative, base, and optimistic scenarios. The analysis indicates this emerging therapeutic class is expected to witness healthy growth over the next decade, driven by encouraging clinical trial results and synergy potential with established therapeutics.PR NewswireKanaph Therapeutics Closes 21M USD Series B FundingKanaph Therapeutics, a South Korea-based biotech company specializing in oncology, auto-immune, and eye diseases, has completed a $21 million Series B funding round with participation from GC Pharma, Kolon Investment, and Timefolio Asset Management. The company has now raised a total of $30 million across its angel, Series A, and Series B rounds. The funding will accelerate clinical development of its TMEkineTM bispecific antibody platform for immuno-oncology and bi-specific Fc fusions for retinal diseases, including a CDO agreement with Samsung Biologics for KNP-301.